Legend Biotech (LEGN) Operating Margin (2024 - 2025)
Legend Biotech (LEGN) posted Operating Margin of 6.43% for Q4 2025, up 59.69% on a QoQ basis from 15.96% in Q3 2025, and up 3609.0% year-over-year from 0.17% in Q4 2024.
Legend Biotech (LEGN) Operating Margin (2024 - 2025) Analysis & Trends
Legend Biotech's Operating Margin history runs 2 years deep, the most recent figure standing at 6.43% for Q4 2025.
- Quarterly Operating Margin rose 3609.0% year-over-year to 6.43% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 20.69% (changed N/A YoY) and the FY2025 annual result came in at 13.27%, up 3607.0% from the prior year.
- Operating Margin was 6.43% for Q4 2025 at Legend Biotech, up from 15.96% in the prior quarter.
- Across five years, Operating Margin topped out at 6.43% in Q4 2025 and bottomed at 43.92% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - | -6.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.43% |
| Sep 30, 2025 | -15.96% |
| Dec 31, 2024 | -42.52% |
| Sep 30, 2024 | -43.92% |